The Differential Effect of NAT2 Variant Alleles Permits Refinement in Phenotype Inference and Identifies a Very Slow Acetylation Genotype

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Ruiz, Jhon D ^a   Martínez, Carmen ^a   Anderson, Kristin ^b   Gross, Myron ^c   Lang, Nicholas P ^d   García Martín, Elena ^a   Agúndez, José A G ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ENZYME VARIANT; PROTEIN VARIANT;

ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DRUG ACETYLATION; FEMALE; GENE DOSAGE; GENOTYPE; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PHENOTYPE; PREDICTION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ACETYLATION; AGED; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; GENOTYPE; HUMANS; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84866098991     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044629     Document Type: Article

References (25)

1. Agundez JA, (2008) N-acetyltransferases: lessons learned from eighty years of research. Curr Drug Metab 9: 463-464.
2. Andrade RJ, Agundez JA, Lucena MI, Martinez C, Cueto R, et al. (2009) Pharmacogenomics in drug induced liver injury. Curr Drug Metab 10: 956-970.
3. Evans DA, Manley KA, Mc KV, (1960) Genetic control of isoniazid metabolism in man. Br Med J 2: 485-491.
4. Evans DA, Storey PB, Wittstadt FB, Manley KA, (1960) The determination of the isoniazid inactivator phenotype. Am Rev Respir Dis 82: 853-861.
5. Agundez JA, del Barrio J, Padro T, Stephens C, Farre M, et al. (2012) Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the Spanish Society of Clinical Pharmacology. Frontiers in Pharmacology 3: 1-6.
6. Hein DW, (2009) N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin Drug Metab Toxicol 5: 353-366.
7. Anderson KE, Sinha R, Kulldorff M, Gross M, Lang NP, et al. (2002) Meat intake and cooking techniques: associations with pancreatic cancer. Mutat Res 506-507: 225-231.
8. Anderson KE, Kadlubar FF, Kulldorff M, Harnack L, Gross M, et al. (2005) Dietary intake of heterocyclic amines and benzo(a)pyrene: associations with pancreatic cancer. Cancer Epidemiol Biomarkers Prev 14: 2261-2265.
9. Zhang J, Zhang X, Dhakal IB, Gross MD, Kadlubar FF, et al. (2011) Sequence variants in antioxidant defense and DNA repair genes, dietary antioxidants, and pancreatic cancer risk. Int J Mol Epidemiol Genet 2: 236-244.
10. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, et al. (1992) Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2: 116-127.
11. Gross M, Kruisselbrink T, Anderson K, Lang N, McGovern P, et al. (1999) Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev 8: 683-692.
12. Miners JO, Birkett DJ, (1996) The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Gen Pharmacol 27: 245-249.
13. McQuilkin SH, Nierenberg DW, Bresnick E, (1995) Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities. Cancer Epidemiol Biomarkers Prev 4: 139-146.
14. Bolt HM, Selinski S, Dannappel D, Blaszkewicz M, Golka K, (2005) Re-investigation of the concordance of human NAT2 phenotypes and genotypes. Arch Toxicol 79: 196-200.
15. Tang BK, Kadar D, Kalow W, (1987) An alternative test for acetylator phenotyping with caffeine. Clin Pharmacol Ther 42: 509-513.
16. Agundez JA, Golka K, Martinez C, Selinski S, Blaszkewicz M, et al. (2008) Unraveling ambiguous NAT2 genotyping data. Clin Chem 54: 1390-1394.
17. Selinski S, Blaszkewicz M, Lehmann ML, Ovsiannikov D, Moormann O, et al. (2011) Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype. Pharmacogenet Genomics 21: 673-678.
18. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, et al. (2002) Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35: 883-889.
19. Leiro-Fernandez V, Valverde D, Vazquez-Gallardo R, Botana-Rial M, Constenla L, et al. (2011) N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. International Journal of Tuberculosis and Lung Disease 15: 1403-1408.
20. Cascorbi I, Brockmoller J, Mrozikiewicz PM, Muller A, Roots I, (1999) Arylamine N-acetyltransferase activity in man. Drug Metab Rev 31: 489-502.
21. Garcia-Martin E, (2008) Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Curr Drug Metab 9: 487-497.
22. Moslehi R, Chatterjee N, Church TR, Chen J, Yeager M, et al. (2006) Cigarette smoking, N-acetyltransferase genes and the risk of advanced colorectal adenoma. Pharmacogenomics 7: 819-829.
23. Walraven JM, Zang Y, Trent JO, Hein DW, (2008) Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2. Curr Drug Metab 9: 471-486.
24. Agundez JA, (2008) Polymorphisms of human N-acetyltransferases and cancer risk. Curr Drug Metab 9: 520-531.
25. Bartsch H, Malaveille C, Lowenfels AB, Maisonneuve P, Hautefeuille A, et al. (1998) Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase in relation to malignant and benign pancreatic disease risk. The International Pancreatic Disease Study Group. Eur J Cancer Prev 7: 215-223.